AFP and hepatocellular carcinoma: Systematic reviews have shown that PIVKA‐II outperforms AFP in detecting HCC across diverse racial groups and sample sizes, as well as in cases of HBV‐related, HCV‐related, or mixed‐etiology HCC [11, 12].